Genedrive Positioned for NHS Tender as Rapid MT-RNR1 Test Expands Across UK NICUs

An announcement from Genedrive ( (GB:GDR) ) is now available.

Genedrive, a Manchester-headquartered pharmacogenetic testing specialist focused on rapid point-of-care diagnostics for acute settings, already supplies two NICE-recommended genetic tests in NHS clinical use, targeting stroke treatment optimisation and prevention of antibiotic-induced hearing loss in newborns. The company aims to scale its UK-developed precision diagnostics using real-world evidence to support broader adoption and commercial growth.

The company has welcomed an NHS England preliminary market engagement notice under the Procurement Act 2023 that will shape a national commercial strategy for rapid MT-RNR1 testing in neonates, a move that could cement its MT-RNR1 kit within standard care. Its test is already in routine use in 14 UK neonatal intensive care units under the PALOH-UK programme and is being rolled out across NHS Scotland, with a potential UK-wide tender anticipated for 2027, signalling a pathway from pilot projects to business-as-usual adoption and offering significant upside for Genedrive’s role in safeguarding babies from antibiotic-induced hearing loss.

Spark’s Take on GDR Stock

According to Spark, TipRanks’ AI Analyst, GDR is a Neutral.

The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).

To see Spark’s full report on GDR stock, click here.

More about Genedrive

Genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company specialising in rapid, point-of-care diagnostics that guide safe and effective drug prescription in emergency and acute care settings. Its CE-IVD approved, NICE-recommended tests include the Genedrive CYP2C19 ID Kit for stroke patients and the Genedrive MT-RNR1 ID Kit to prevent antibiotic-induced hearing loss in newborns, with a focus on embedding UK-developed precision diagnostics into routine care and expanding internationally.

Average Trading Volume: 5,796,825

Technical Sentiment Signal: Strong Sell

Current Market Cap: £15.25M

Learn more about GDR stock on TipRanks’ Stock Analysis page.